Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will learn from this study if the CyberKnife radiosurgery (CK RS) treatment of patients with 1-3 versus 4 or more brain metastases results in the same overall survivals. The importance of this new knowledge will be to determine the treatment efficacy of CK RS with 1-3 versus 4 or more brain metastases. The outcome of this trial would give data to support either the continuation or modification of the CK RS treatment of patients with brain metastases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases

NCT00928226

Brain Cancer Neoplasm Metastasis Cancer of Brain and Nervous System +1 more

COMPLETED NA

Combined Gamma Knife/Linac Radiosurgery for Large Brain Tumors / Metastases

NCT07162246

Brain (Nervous System) Cancers Brain Metastasases SRS

RECRUITING PHASE2

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

NCT03750227

Malignant Solid Neoplasm Metastatic Malignant Neoplasm in the Brain

RECRUITING PHASE3

Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence

NCT03303365

Brain Metastases Adult Solid Tumor

COMPLETED NA

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

NCT03741673

Malignant Neoplasm Metastatic Malignant Neoplasm in the Brain

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is registry-based cohort study of patients with brain metastases treated at Stanford University Medical Center (SUMC) with CyberKnife radiosurgery (CK RS). It has two components: (1) a retrospective follow-up of patients treated since 2006, and (2) the accrual of a new cohort of patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter. The primary aim of this study is to estimate the effect of the number of brain tumor metastases on survival after adjusting for known risk factors for mortality.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain and Nervous System

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

retrospective cohort

retrospective follow-up of patients treated since 2006

No interventions assigned to this group

prospective cohort

patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. the presence of a tumor metastasis or tumor metastases to the brain as manifested by the neurological examination and visibility of the metastatic lesion(s) on MRI and CT scans
2. a Karnofsky performance status (KPS) score of greater than or equal to 60.

Minimum Eligible Age

21 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No